In this episode, Tom sits down with chemist Dr. Markus Roggen of Delic Labs to talk about his journey to help cannabis and psilocybin processors and researchers optimize their processes, make better products and uncover better data about psychedelics. Dr. Roggen and Tom discuss many of the different research projects that he has been involved in and the insights that he and his teams have been able to gain about extraction science, harvesting psychedelic mushrooms, and cannabinoid chemistry. Finally, we discuss some of the work that Delic Labs is doing with psychedelics and the role of pharma over recreation in the efforts to measure and advance the psychedelic-wellness industry.

Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development in Canada. Delic Labs was initially founded as Complex Biotech Discovery Ventures by Dr. Roggen and Prof. Dr. Glenn Sammis in 2018, and rebranded after the sale to Delic Corp.

Dr. Roggen received his M/Sci degree from Imperial College, London, UK in 2008. He then pursued his graduate degree in organic chemistry at the Federal Institute of Technology in Zürich (ETHZ), where he received his PhD in 2012. Dr. Roggen was awarded a DAAD postdoctoral fellowship to pursue further training in physical organic chemistry at The Scripps Research Institute in La Jolla in 2013-2014. He then entered the cannabis industry in 2014 and since has held executive positions in analytical and production companies. His research into process optimization and analytical methods has been recognized with a number of awards, ElSohly Award of the American Chemical Society, Cannabis Scientist Power List 2020 & 2021, and 40 under 40 by Marijuana Venture Magazine among others. Dr. Roggen is also a trusted advisor and mentor to multiple startups, startup accelerators and organizations. 

Learn more about Delic Labs at: https://deliclabs.com/